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Repeated injection of atrial natriuretic peptide [5045 
(a-hANP) in normal man: cardiovascular and 
renal actions 
] Potratz, G Müller-Esch, R Gerzer, P Ball , J A t l , and P C 
Scriba, D e p t s . M e d i c i n e and Biochem. E n d o c r i n o l o g y , M e d i c a l 
U n i v . , Lübeck, and D e p t . M e d i c i n e , U n i v . München, F R G 
In 6 healthy volunteers, 200//g of a - h A N P were given twice 
as an intravenous bolus injection within 30 min. M-mode-
echocardiography was performed and serum levels of A N P 
and c G M P as wel l as c G M P - , sodium- and potassium excre-
tion were determined. 
After each injection, a clear-cut increase of stroke volume by 
15%, ejection fraction by 16% and cardiac index by 16% was 
observed (p < 0.01). Hemodynamic changes were most pro-
nounced from 10 to 15 m i n after each administration and 
reached baseline values another 15 m i n later. Serum A N P 
rose 20fold; c G M P increased from 3.2 ± 1 . 1 to 25.0 ± 6.7 
nmol/1 within 10 m i n after the first injection and from 20.0 ± 
6.0 before the second administration to 32.7 ± 11.1 nmol/1 
another 10 m i n later. Urinary c G M P excretion rose 9fold, 
urine volume 12fold, sodium excretion 6fold and potassium 
excretion doubled. These renal actions were still present for at 
least 90 min later. N o severe side effects were observed. 
C o n c l u s i o n s : 1. Renal effects caused by a - h A N P are more 
persistent than its cardiovascular actions. 2. Using a dosage 
interval of 30 m i n reproducable improvement of myocardial 
Performance can be obtained by a second bolus injection. 3. 
The role of c G M P as a marker for A N P is confirmed. 
